Black Diamond Therapeutics Investor Presentation — November 2019

Document content

Precision Oncology Medicines Addressing

Treatment Resistant Cancers

November 20, 2019Disclaimer

Forward -Looking Statements

Statements in this Presentation that are not statements of historical fact are forward -looking statements. Such forward -looking statements include,

without limitation, statements regarding our research and clinical development plans, business strategy and plans, regulatory matters, objectives of

management for future operations, market size and opportunity, our ability to complete certain milestones and our expectation s regarding the relative

benefits of our drug candidates versus competitive therapies. Words such as “believe,” “can”, “continue,” “anticipate,” “could,” “estimate,” “plan,”

“predict,” “expect,” “intend,” “will,” “may,” “goal,” “upcoming,” “near term”, “milestone”, “potential,” “target” or the negativ e of these terms or similar

expressions are intended to identify forward -looking statements, though not all forward -looking statements necessarily contain t hese identifying words.

Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward -

looking statements. Risks that contribute to the uncertain nature of the forward -looking statements include, without limitation: our preclinical studies

and clinical trials may not be successful; regulatory authorities, including the U.S. Food and Drug Administration (FDA) may not agree with our

interpretation of the data from clinical trials of our drug candidates; we may decide, or regulatory authorities may require us, to conduct additional

clinical trials or to modify our ongoing clinical trials; we may experience delays in the commencement, enrollment, completion o r analysis of clinical

testing for our drug candidates, or significant issues regarding the adequacy of our clinical trial designs or the execution of our clinical trials may arise,

which could result in increased costs and delays, or limit our ability to obtain regulatory approval; our drug candidates may not receive regulatory

approval or be successfully commercialized; unexpected adverse side effects or inadequate therapeutic efficacy of our drug candi dates could delay or

prevent regulatory approval or commercialization; and we may not be able to obtain additional financing. These forward -looking s tatements should not

be taken as forecasts or promises nor should they be taken as implying any assurance or guarantee that the assumptions on whi ch such forward -looking

statements have been made are correct or exhaustive. You are cautioned not to place undue reliance on these forward -looking stat ements, which speak